Quotables
"What, sir, would you make a ship sail against the wind and currents by lighting a bonfire under her deck? I pray you, excuse me, I have not the time to listen to such nonsense."
Napoleon Bonaparte ; When told of the Robert Fulton steamboat
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6982319 | Antibodies which bind specifically to activin receptor-like kinases A new receptor family has been identified, of activin-like kinases. Novel proteins have activin/TGF-β-type I receptor functionality, and have consequential diagnostic/therapeutic utility. They may have a serine/threonine kinase domain, a DFKSRN or DLKSKN sequence i... | 01/03/2006 |
| 6617575 | Modified ion source targets for use in liquid maldi MS The present invention pertains to modified ion source targets suitable for use with liquid matrices (e.g., glycerol and lactic acid) in liquid matrix-assisted laser desorption/ionisation (MALDI) methods, as used, for example, in infrared (IR) liquid MALDI... | 09/09/2003 |
| 6217868 | Methods for detecting cancer cells by using humanized antibodies which bind specifically to FB5 antigen The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide rang... | 04/17/2001 |
| 6218516 | Antibodies specific for the extracellular domain of NYK/flk-1 protein and uses thereof The present invention relates to immunointeractive molecules and their use in therapeutics and diagnostics. More particularly, the present invention provides antibodies that bind to NYK/flk-1 receptors, in particular the extracellular domain.... | 04/17/2001 |
| 6210886 | Method for diagnosing multiple myeloma by determining tumor rejection antigen precursors Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also mon... | 04/03/2001 |
| 6190640 | Method for treating neoplasia using humanized antibodies which bind to antigen A33 The invention involves the therapeutic use of humanized antibodies, fragments, etc., which bind to the antigen A33. These antibody molecules are useful in the treatment of various neoplasias, including colon cancer. Various modes of administration, and do... | 02/20/2001 |
| 6174692 | MAGE-10 encoding cDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.1... | 01/16/2001 |
| 6171806 | Isolated peptide defined by SEQ ID NO: 17 and uses thereof Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are not derived from tyrosinase, which has previously been identified as a tumor rej... | 01/09/2001 |
| 5851523 | Isolated, peptides derived from MAGE tumor rejection antigen precursors which complex with HLA-A2 molecules and uses thereof Tumor rejection antigens derived from MAGE tumor rejection precursors have been identified. These "TRAS" bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cel... | 12/22/1998 |
